Neovacs Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
ALNEV
- Investments
-
6
- Share Price
-
$0.05
- (As of Friday Closing)
Neovacs General Information
Description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Contact Information
Website
www.neovacs.comCorporate Office
- 14 rue de la republique
- 92150 Suresnes
- France
Corporate Office
- 14 rue de la republique
- 92150 Suresnes
- France
Neovacs Stock Performance
As of 20-Nov-2026, Neovacs’s stock price is $0.05. Its current market cap is $8.05K with 160K shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.05 | $0.05 | $0.04 - $310.84 | $8.05K | 160K | 136K | -$61.1K |
Neovacs Financials Summary
As of 30-Jun-2026, Neovacs has a trailing 12-month revenue of $327K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 161 | 165 | ||
| Revenue | 327 | 365 | 396 | 578 |
| EBITDA | (6,014) | (5,819) | (30,368) | (6,556) |
| Net Income | (4,772) | (5,524) | (35,617) | (9,461) |
| Total Assets | 25,351 | 26,040 | 22,966 | 58,102 |
| Total Debt | 805 | 631 | 240 | 719 |
Neovacs Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neovacs Patents
Neovacs Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022330351-A1 | Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof | Pending | 20-Aug-2021 | ||
| CA-3229324-A1 | Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof | Pending | 20-Aug-2021 | ||
| EP-4387648-A1 | Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof | Pending | 20-Aug-2021 | ||
| US-20250312427-A1 | Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof | Pending | 20-Aug-2021 | ||
| WO-2023021195-A1 | Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof | Inactive | 20-Aug-2021 | A61K39/0008 |
Neovacs Signals
Neovacs Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Neovacs Investments (6)
Neovacs’s most recent deal was a Early Stage VC with NETRI for . The deal was made on 26-Apr-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NETRI | 26-Apr-2022 | Early Stage VC | Medical Supplies | ||
| Signia Therapeutics | 20-Nov-2021 | Early Stage VC | Drug Discovery | ||
| Joint Venture (Neovacs / Priority One Canine) | 30-Sep-2021 | Joint Venture | Other Healthcare Services | ||
| The Famar Factory | 29-Jun-2020 | Corporate | Buildings and Property | ||
| AMEGABiotech (Interferon Alpha Manufacturing Technology) | 15-Nov-2016 | Corporate Asset Purchase | Buildings and Property |
Neovacs ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Neovacs Exits (2)
Neovacs’s most recent exit was on 20-Nov-2021 from Signia Therapeutics. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Signia Therapeutics | 20-Nov-2021 | Completed |
|
||
| The Famar Factory | 29-Jun-2020 | Corporate | Completed |
Neovacs FAQs
-
When was Neovacs founded?
Neovacs was founded in 1993.
-
Where is Neovacs headquartered?
Neovacs is headquartered in Suresnes, France.
-
What is the size of Neovacs?
Neovacs has 11 total employees.
-
What industry is Neovacs in?
Neovacs’s primary industry is Drug Discovery.
-
Is Neovacs a private or public company?
Neovacs is a Public company.
-
What is Neovacs’s stock symbol?
The ticker symbol for Neovacs is ALNEV.
-
What is the current stock price of Neovacs?
As of 20-Nov-2026 the stock price of Neovacs is $0.05.
-
What is the current market cap of Neovacs?
The current market capitalization of Neovacs is $8.05K.
-
What is Neovacs’s current revenue?
The trailing twelve month revenue for Neovacs is $327K.
-
What is Neovacs’s annual earnings per share (EPS)?
Neovacs’s EPS for 12 months was -$61.1K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process